CRG-023

CARGO is advancing a pipeline
of transformational next-generation
CAR T-cell therapies for cancer

3D molecule redering
ProgramTarget(s)Indication(s)DiscoveryIND-enablingPhase 1Phase 2Phase 3Commercial rights
Firi-cel* (CRG-022) CD22 R/R LBCL - post CD19 CAR T
 
commercial rights logo
Firi-cel* (CRG-022) CD22 LBCL - CAR T naïve(1)
 
commercial rights logo
Firi-cel* (CRG-022) CD22 Pediatric B-ALL
 
commercial rights logo
CRG-023 (tri-specific CAR T with CD2 co-stimulation) CD19
CD20
CD22
B-cell malignancies
 
commercial rights logo
Firi-cel* (CRG-022)
DiscoveryIND-enablingPhase 1Phase 2Phase 3Commercial rights
Target: CD22
Indication: R/R LBCL - post CD19 CAR T
Target: CD22
Indication: LBCL - CAR T naïve(1)
Target: CD22
Indication: Pediatric B-ALL
CRG-023 (tri-specific CAR T with CD2 co-stimulation)
DiscoveryIND-enablingPhase 1Phase 2Phase 3Commercial rights
Target: CD19
CD20
CD22
Indication: B-cell malignancies

CARGO is developing multi-specific CAR T-cell therapies with CD2 co-stimulation designed to overcome multiple resistance mechanisms – antigen loss, co-stimulation (CD58) loss and lack of persistence. With a multi-targeted approach, it has the potential to treat several hematologic malignancy types.

Our most advanced preclinical program, CRG-023, incorporates a tri-specific CAR to address either tumor antigen loss (e.g., CD19) or low-density antigen expression, loss of costimulation (e.g., CD58) and lack of T-cell persistence. CRG-023 is designed to target tumor cells with three B-cell antigen targets, CD19, CD20 and CD22. This product candidate also integrates a CD2 costimulatory domain into the tri-specific CAR T-cell to counter a target-independent mechanism, the downregulation of COSS (the ligand of the CD2 costimulatory receptor), that leads to resistance to CAR T-cells and other immune therapies.